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Abstract
West Nile virus (WNV) is a flavivirus transmitted between certain species of birds and mosquito 
vectors. Tangential infections of equids and subsequent equine epizootics have occurred 
historically. Although the attack rate has been estimated to be below 10%, mortality rates can 
approach 50% in horses that present clinical disease. Symptoms are most commonly presenting in 
the form of encephalitis with ataxia as well as limb weakness, recumbency and muscle 
fasciculation. The most effective strategy for prevention of equine disease is proper vaccination 
with one of the numerous commercially available vaccines available in North America or the 
European Union. Recently, WNV has been increasingly associated with equine epizootics 
resulting from novel non-lineage-1a viruses in expanding geographic areas. However, specific 
experimental data on the virulence of these novel virus strains is lacking and questions remain as 
to the etiology of the expanded epizootics: whether it be a function of inherent virulence or 
ecological and/or climactic factors that could precipitate the altered epidemiological patterns 
observed.
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1. Introduction
West Nile virus (WNV) is one of more than seventy viruses of the family Flaviviridae of the 
genus Flavivirus that is comprised of viruses that form enveloped spherical shaped virions 
encompassing a single-stranded RNA molecule of positive polarity that is approximately 11-
kb in length (Harris et al., 2006) (Fig. 1a and b). The genomic RNA of flaviviruses encodes 
three structural proteins (C-prM-E) at the 5′ third of the genome and seven nonstructural 
proteins (NS1-NS2A-NS2B-NS3-NS4A-NS4B-NS5) in the remaining two-thirds of the 
genome. These are flanked by 5′ and 3′ untranslated regions involved in transcription and 
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translation (Heinz et al., 2000). The viral structural proteins are involved in RNA 
encapsidation [Capsid (C)] and as scaffolding and physical structures for interactions that 
facilitate receptor-mediated endocytosis and envelope fusion [pre-membrane (prM/M) and 
envelope (E) proteins]. All seven of the nonstructural proteins have been identified to be 
involved in different functions associated withRNA synthesis such as RNA dependent RNA 
polymerase and methyltransferase (NS5), as well as helicase and protease (NS3) functions. 
Both structural and nonstructural proteins are translated as one large polyprotein that is 
cleaved into the respective viral proteins by both host and viral proteases both co- and post-
translationally (Chambers et al., 1990).
Although the genus is comprised predominantly of viruses transmitted between vertebrate 
hosts and arthropod vectors such as mosquitoes and ticks, viruses for which no vectors have 
been identified [no known vectors] (Billoir et al., 2000) and viruses with no identified 
vertebrates hosts [insect-specific flaviviruses] have been described within the genus (Cook 
et al., 2011). Serologically, flaviviruses have been classified into at least eight antigenic 
serocomplexes based on cross neutralization characteristics with antisera generated between 
different viruses. Viruses belonging to the Japanese encephalitis (including WNV), tick-
borne encephalitis, yellow fever and dengue serocomplexes are associated with the highest 
incidence of disease in humans and animals (Westaway et al., 1985).
2. West Nile virus - virology and molecular biology
West Nile viruses can be designated into at least four phylogenetic groups or lineages based 
on sequence analyses (May et al., 2011). Lineage 1 can be further subdivided (Fig. 2) into 
three clades or sublineages (a–c). Clade 1a encompasses a wide geographic range of isolates 
made from Africa, the Middle East, India, Europe and the western hemisphere while clade 
1b represents Kunjin viruses from Australasia and clade 1c is comprised of more recent 
viruses from India (May et al., 2011). Clade 1c has been proposed also as new WNV lineage 
5 (Bondre et al., 2007). Prior to an isolation in Hungary in 2004 (Bakonyi et al., 2006), 
lineage 2 WNVs had been isolated exclusively from African transmission cycles (with the 
exception of a single isolate in 1968 from Cyprus) (McMullen et al., 2013). Lineage 2 
viruses have been circulating most commonly in Sub-Saharan Africa and Madagascar 
(Botha et al., 2008; McMullen et al., 2013). Lineage 2 WNVs, like lineage 1 strains, have 
recently undergone a radiation from Africa in which these viruses have been associated with 
human and equine outbreaks in Hungary (Kutasi et al., 2011; Bakonyi et al., 2013), Romania 
(Sirbu et al., 2011), Russia (Platonov et al., 2011) and Greece (Papa, 2012) as well as 
enzootic/epizootic activity in Italy (Bagnarelli et al., 2011; Savini et al., 2012) and epizootic/
epidemic activity in South Africa (Venter et al., 2009). Lineage 3 (Rabensburg) virus is 
represented by two isolates from the Czech Republic (Bakonyi et al., 2005) that replicate 
very poorly in vertebrate hosts and have been postulated to be potentially arthropod-specific 
(Aliota et al., 2012) while lineage 4 WNV is comprised of tick isolates made from the 
Caucas Mountians in southern Russia (Prilipov et al., 2001). There currently is no evidence 
that lineage 3 or 4 WNVs have the capacity to elicit disease in humans or horses.
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West Nile virus is grouped into the Japanese encephalitis serocomplex along with other 
viruses transmitted between vertebrate hosts and mosquitoes such as Japanese encephalitis 
virus (JEV), Murray Valley encephalitis virus (MVEV) and St. Louis encephalitis virus 
(SLEV). Viruses belonging to this antigenic serocomplex inclusive of WNV utilize avian 
hosts and mosquitoes of the genus Culex for transmission in nature; however, all of these 
viruses can tangentially infect humans and a number of domestic animals. Although 
encephalitic syndromes can present, most domestic animals and humans fail to generate a 
viremia sufficient to infect mosquito vectors and are thusly referred to as “dead-end” hosts 
as their infection does not contribute to additional cases either directly or indirectly through 
infection of an arthropod vector (Fig. 3). Encephalitis in equids has been described for JEV, 
MVEV as well as WNV; however, WNV is responsible for the vast majority of equine 
flaviviral encephalitis infections worldwide with more than 600 confirmed cases reported in 
the United States in 2012 alone (United States Department of Agriculture, 2012). Viruses 
within the JEV serocomplex have a worldwide distribution with MVEV circulating in 
Australia, Papua New Guinea and Irian Jaya (Knox et al., 2012), JEV circulating from 
Pakistan-India east through northwestern Australia and SLEV circulating in North, Central 
and South America. West Nile virus has a much more extensive geographic range having 
been identified on every continent with the exception of Antarctica. Following its initial 
isolation from a febrile woman in the West Nile District of Uganda in 1937 (Smithburn et 
al., 1940), enzootic WNV transmission foci have been described in South Africa, East 
Africa, the Middle East, Pakistan and Australia (Kunjin). Subsequently, periodic epidemics/
epizootics of human and equine disease were described in Egypt (1950s), South Africa 
(1970s), Israel (1950s); however, an observed increase in the frequency and distribution of 
these episodic events became evident in the mid 1990s. Incursions of WNV into Europe 
likely through bird migration directly from North Africa and East Africa through the Middle 
East migratory routes have been supported by viral sequence analyses from these respective 
geographic locations (Charrel et al., 2003). Human encephalitis epidemics in 1996 in 
Bucharest, Romania (Tsai et al., 1998) and 1999 in Volgograd, Russia (Platonov, 2001) as 
well as Israel in 1998–2000 preceded the first report of WNV in North America in New 
York City in 1999 in which avian deaths were associated with human encephalitis cases 
(Lanciotti et al., 1999) with a very similar genotype virus. Serological evidence indicated 
that within three years of first being identified in North America, WNV had spread to the 
islands of the Caribbean, Central America (Hobson-Peters et al., 2011) and portions of 
South America, and active transmission was documented westward across the entire North 
American continent and north into Canada. Despite the fact that serological evidence of 
WNV transmission in Latin America has existed for many years (Komar and Clark, 2006), 
there has been a surprisingly low incidence of equine disease in Mexico, Central America, 
the Caribbean islands and South America as compared to the United States and Canada. 
Interestingly, several cases of equine encephalitis were reported in a more temperate region 
of Argentina in 2006 (Morales et al., 2006), indicating the potential that climactic factors 
could restrict disease presentation in humans and equids via differences in the force of 
transmission or the potential modulating effects of host diversity (Ezenwa et al., 2006; 
Swaddle and Calos, 2008) in different biomes or the presence of immune responses against 
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heterologous flaviviruses that could afford protection against disease presentation. Sequence 
analyses of the few isolates of WNV that have been made in Mexico (Beasley et al., 2004) 
not adjacent to the U.S.–Mexican border as well as the Argentinean isolates from 
encephalitic horses indicate that the effects of genetic drift and the introduction of lesser 
virulent genotypes (Morales et al., 2006; Brault et al., 2011; Langevin et al., 2011) could 
play a role in reduced virulence potential.
4. Epidemiology in horses
Although WNV had been associated with sporadic epidemics in Egypt since the 1950s, 
epizootics in equids were not reported. However, in 1959 sporadic disease associations in 
equids were made, high seroprevalence rates were found and isolation of WNV from 
diseased horses were reported (Schmidt and Elmansoury, 1963). Fig. 4 consists of a map 
depicting temporal and geographic locations of WNV equine outbreaks. In France, a WNV 
outbreak occurred in 1962 in the Camargue region with several wild and domestic horses 
affected (Murgue et al., 2001b). Other cases were reported in 1965 in this region as well. In 
the 1990s an increase in magnitude of equine WNV disease cases was observed. In 
Morocco, over 90 equids were affected in an outbreak in 1996 (Murgue et al., 2001a). Two 
years later, WNV infection in 14 horses in Tuscany were reported (Hubalek and Halouzka, 
1999; Cantile et al., 2001). In the same year, 18 horses with encephalomyelitis tested 
positive for WNV neutralizing antibodies in Israel with a concurrent isolation of WNV from 
a stork (Murgue et al., 2001a). In 1999, WNV first reached the Western hemisphere in North 
America and has subsequently spread throughout the North American continent and into 
South America. Each year equine infections have been detected with a peak of 15,257 cases 
in the U.S. reported during 2002 (APHIS, 2012). In 2000 and 2003, WNV infections in 
horses were once again reported from southern France (76 equine cases in 2000) (Murgue et 
al., 2001b; Mailles et al., 2003) and 2000 in Israel (131 equine cases) (Steinman et al., 
2002).
Clearly, the incidence of disease in equids has increased significantly since the mid 1990s 
concomitant with the radiation of lineage 1a viruses. In fact, comparison of North American 
with European equine exposures demonstrate similarly low attack rates of approximately 5% 
(Nielsen et al., 2008). The effects on transmission due to environmental factors could play a 
significant role in the etiology of equine outbreaks due to the requirements for high infection 
rates for disease to be observed with various WNV lineage viruses. Equine WNV 
encephalitis cases increased markedly following the initial reports of diseased horses in New 
York State in 1999 as the virus moved westward (United States Department of Agriculture, 
2012). The increase in reported equine cases that peaked in 2002 was associated with 
movement of the virus into areas in which Culex tarsalis mosquitoes served as efficient 
vectors for transmission (Goddard et al., 2002). Licensure of a killed WNV vaccine in late 
2002 (Ng et al., 2003) resulted in a dramatic reduction in the subsequent number of equine 
encephalitis cases reported in 2003 despite the large increase in human cases that year 
(United States Department of Agriculture, 2012), indicating the efficacy of equine 
vaccination. In some instances in Europe, equine cases have been observed without 
substantial human disease being reported, such as in Tuscany, Italy (1998) (Autorino et al., 
2002) and Camargue (Pantheir et al., 1966), France (2000); however, in North America 
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equine and human cases have demonstrated similar incidence patterns, both before and after 
widespread vaccination of horses (Ward and Scheurmann, 2008). Since 2010, WNV 
infections among horses repeatedly were reported in the Mediterranean basin and other 
European countries, namely in Bulgaria, Croatia, Greece, Italy, Macedonia, Morocco, 
Portugal, Romania and Spain (Barros et al., 2011; Garcia-Bocanegra et al., 2011; OIE, 
2012). The aforementioned WNV equine epizootics before 2007 were associated with 
lineage 1 viruses. After that year, lineage 2 viruses, which were previously considered to be 
less pathogenic than lineage 1 viruses, have been identified as etiological agents of severe 
WNV outbreaks in horses in South Africa and Hungary (Venter et al., 2009; Kutasi et al., 
2011). Lineage 2 WNVs have also been associated with an ever increasing incidence of 
equine encephalitis in both areas associated with historical transmission such as South 
Africa (Venter et al., 2009; Venter and Swanepoel, 2010) as well as Europe (Kutasi et al., 
2011). Once believed to be of low pathogenic potential due to high seroprevalence rates in 
equids in South Africa with minimal disease presentation (Guthrie et al., 2003), lineage 2 
WNVs are being reevaluated as an emerging zoonotic disease threat for humans and 
livestock. In 2011 an equine encephalitis outbreak was observed in New South Wales, 
Australia in which Kunjin virus (WNV lineage 1b) was isolated and implicated as the 
etiologic agent in the first reported equine encephalitis outbreak attributed to this WNV 
genotype (Tee et al., 2012). In contrast to many lineage 1b viruses previously characterized, 
sequence analyses of this lineage 1b equine isolate demonstrated the virus to have a 
glycosylated envelope protein, and experimental inoculations of mice demonstrated the virus 
to have an intermediate virulence between that of lineage 1a and other lineage 1b viruses 
(Frost et al., 2012). To date, no specific genetic determinants have been associated with 
altered pathogenesis in horses despite virulence determinants having previously been 
associated with lineage 1 virulence differences in birds (Brault et al., 2007; Murata et al., 
2010) and mice (Beasley et al., 2002, 2005).
5. Transmission of WNV
While WNV is transmitted and maintained in an enzootic mosquito-bird cycle, equids can 
be infected by bridge vectors and develop subclinical infection or neurological disease. 
Mosquito species that are believed to most likely transmit WNV to equines are Culex 
pipiens and Culex tarsalis in North America and Culex pipiens complex mosquitoes in 
Europe (Nielsen et al., 2008; Sebastian et al., 2008; Munoz et al., 2012).
Like humans, horses are considered to be dead-end hosts in that they develop only short and 
low magnitude viremia levels. In horses exposed to infected mosquito bites, Bunning et al. 
demonstrated a maximum serum viremia titer of 103 pfu/ml serum with the viremia lasting 
up to six days and numerous subsequent studies with experimental infection of horses have 
corroborated this concept (Bowen, unpublished). Such a low serum viremia coupled with the 
small volume of a blood meal imbibed by a mosquito (approximately one microliter) would 
make it unlikely that the midgut epithelia of a mosquito would be exposed to a single 
infectious unit of virus. Vector competency studies have confirmed that these serum 
viremias are not conducive to mosquito infection from WNV infected horses (Turell et al., 
2008). Only one horse of 12 infected in the Bunning study became clinically ill with severe 
encephalomyelitis and relatively high titers of virus were observed in tissues (104.0–106.8 
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pfu/tissue; Bunning et al., 2002). Other challenge studies have demonstrated maximum 
viremia levels of 1530 pfu/ml or lower which lasted 1–4 days, both with lineage 1 and 2 
WNVs. Seroconversion occurred after 7 days post-infection with neutralizing titers of 1:320 
(Minke et al., 2004; Seino et al., 2007; Minke et al., 2011).
6. Clinical symptoms in horses
Clinical signs resulting from infection of horses with WNV have been described from 
naturally occurring cases and experimental infections. Most horses seroconvert without 
clinical disease after exposure to WNV, similar to what has been described in humans. In 
approximately 8% of exposed naive horses, severe WNV disease with neurological 
symptoms develop (Gardner et al., 2007). Affected horses develop encephalomyelitis with 
ataxia as the predominant clinical presentation. Similar common symptoms include 
weakness of the limbs, recumbency and muscle fasciculation. Fewer horses present with 
fever, cranial nerve deficits such as a drooping lip and/or facial or muscle fasciculation; 
fever is inevitably observed during the course of experimental infection, but typically occurs 
before obvious neurologic signs. Amongst fever, also depression, anorexia, colic or 
lameness can be one of the first recognized signs in diseased animals (Long, 2006). 
Hyperesthesia, teeth grinding, muscular tremor, photophobia and blindness have been 
observed in a small proportion of clinical cases (Murgue et al., 2001b; Ostlund et al., 2001; 
Abutarbush et al., 2004; Garcia-Bocanegra et al., 2011). Abnormal behavior such as 
depression, somnolence, disorientation, hyperexcitability and aggressive behavior as well as 
changes in personality have also been associated with WN infection in equids (Ostlund et 
al., 2001; Porter et al., 2003; Abutarbush et al., 2004; Long, 2006; Garcia-Bocanegra et al., 
2011). Excellent illustrations of the clinical signs of WN disease in horses are given by the 
following video: http://www.youtube.com/watch?v=BJtVP5Bd5bs. The fatality rate in 
diseased animals is high in horses and ranges from 22% to 44% (Murgue et al., 2001a; 
Ostlund et al., 2001; Schuler et al., 2004; Garcia-Bocanegra et al., 2011). In the 2000 French 
equine epizootic, fever as well as paresis and paralysis in addition to ataxia were frequent 
clinical signs (Murgue et al., 2001b). Fever was also common in hospitalized horses from 
Florida. (Porter et al., 2003). In a report from Italy, paresis of limbs, progressing to 
tetraplegia and recumbency predominated (Cantile et al., 2001). Disease presentation has 
been observed to be very similar between WNV lineage 1 and lineage 2 WNV infected 
equids (Venter et al., 2009; Kutasi et al., 2011), however, controlled experimental infections 
of equids have not been conducted in order to specifically address potential pathogenic 
differences between viruses of the two lineages.
A variety of horse breeds as well as a wide age distribution have been observed to present 
with WNV disease; however, the case fatality rate has been noted to be higher in older 
horses (Schuler et al., 2004). In the western U.S., females were 2.9 times more likely to 
succumb to infection as males (Salazar et al., 2004). Duration of illness in recovering horses 
ranges from two to seven days in mildly affected individuals and in excess of 20 days to 
several months for regeneration to their original condition of more severe disease cases 
(Trock et al., 2001; Venter et al., 2009). Up to 20% of diseased horses show residual 
sequelae such as weight loss, lethargy, ataxia or cranial nerve deficits (Salazar et al., 2004).
Angenvoort et al. Page 6













Similar to the high proportion of subclinical disease in natural infections, WNV challenge 
experiments have often failed to provoke severe clinical symptoms, sometimes with the 
exception of mild muscle fasciculation (Minke et al., 2004; Siger et al., 2004; Castillo-
Olivares et al., 2011). Bunning et al. (2002) observed fever and severe neurological signs in 
one of the challenged individuals, amounting to an attack rate of approximately 8%. Only 
after intrathecal challenge with WN lineage 1 virus did horses develop moderate to severe 
neurological signs, with 50% developing fever and all requiring euthanasia (Seino et al., 
2007). Similar experiments performed by intrathecal inoculation with a lineage 2 WNV lead 
to hyperthermia, muscle fasciculation and tremor, abnormal mentation, gait deficiency, 
anorexia and lip twitching as well as head shaking with an associated mortality rate of 30% 
(Minke et al., 2011).
Innate immune response is key to resist WNV infection (Samuel and Diamond, 2006). For 
mice it was shown that the interferon system is an important factor for this, as mice lacking 
Interferon type I receptors are highly susceptible to WNV infection (Samuel and Diamond, 
2005). Moreover, there are hints that different WNV genotypes have differences in their 
ability to interfere in interferon signaling (Keller et al., 2006). OAS genes are induced by 
interferon. OAS proteins are antiviral proteins that indirectly activate Ribonuclease L, which 
can degrade viral RNA. Host genetic studies have indicated that polymorphisms in equine 
OAS 1 gene contribute to WNV susceptibility in horses. These polymorphisms were located 
in the interferon-inducible promoter (Rios et al., 2010). There are further studies needed to 
evaluate if there are more factors that modulate innate response to WNV in equines and 
contribute to susceptibility and resistance.
7. Pathology in horses
Pathologic alterations and immunhistochemical findings in natural WNV infected horses 
from Italy and the United States, respectively, were described by Cantile et al. (2001). WNV 
infection in horses is proposed to be limited to the CNS. In some cases, gross macroscopic 
changes such as petechiae in the rhombencephalon and spinal cord have been observed. 
Microscopically, mild to severe polioencephalomyelitis particular of lower brain stem and 
ventral horns of the thoracolumbar spinal cord have been detected. Interestingly, more 
widespread tissue distribution of U.S. horses has been observed than that noted in the Italian 
horses with additional involvement of basal nuclei, thalamus and midbrain. Perivascular 
infiltrates, glial nodules, neutrophils, hemorrhages and occasionally neuronophagia are 
common changes, and the cerebral cortex is spared. The quantity of WNV antigen detected 
by immunohistochemistry is generally low in relation to pathologic alterations, so that an 
immunopathologic process in equine WNV-induced disease has been considered. Due to the 
paucity of detected WNV antigen in endothelial cells, WNV neuroinvasion could occur 
through the olfactory neurons. Additionally, perivascular cuffing of lymphocytes within the 
perineuronal area of dorsal ganglia and moderate to severe hemorrhage in the gray matter, 
white matter and meninges of cervical, thoracic and lumbar segments of spinal cord were 
noted in Kentucky in 2002 (Sebastian et al., 2008).
Results from intrathecal challenge demonstrate corresponding histopathologic alterations as 
seen in natural infections (Seino et al., 2007). The same has applied to experimental 
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infection of equines with WNV lineage 2 viruses. No gross lesions were observed, but 
microscopically very mild to moderate to severe encephalitis with alterations especially in 
brainstem and spinal cord have been reported (Minke et al., 2011).
8. Diagnosis
There are no pathognomonic signs of WN in horses, and depending on geographic location 
and season, a number of other pathogens induce similar or identical clinical disease, 
including New World equine alphaviruses, equine herpes virus 1 and rabies virus in the U.S. 
and rabies, Borna and equine herpes virus 1 in the E.U. Acute WNV infections in equines 
can be diagnosed by the detection of the virus genome by real-time RT-PCR (syn. qRT-
PCR) or by the demonstration of IgM antibodies by ELISA. A variety of well-functioning 
qRT-PCR methods have been published to date. Primer combinations should be selected 
carefully as not all work for WNV strains of both lineages (Eiden et al., 2010). The major 
difficulty with the qRT-PCR is the phenomenon that WNV infections in horses coincide 
only with a rather short viremic phase (4–6 days; Figs. 5 and 6) that is cleared by the onset 
of clinical disease (Bunning et al., 2002; Siger et al., 2004) so that only positive results are 
meaningful in a diagnostic sense. Diagnosis of WN in horses is therefore most commonly 
achieved by demonstrating anti-viral IgM at the time of clinical disease or by demonstration 
of viral antigens or RNA in nervous tissue collected post-mortem.
ELISAs are usually used for the demonstration of WNV-specific (IgM and IgG) antibodies 
and the presence of a high level of IgM antibodies is the best serological indication for a 
recent infection, as in horses they were shown to exist less than three months (Castillo-
Olivares and Wood, 2004) in contrast to humans in which IgM titers may persist longer 
(Roehrig et al., 2003; Papa et al., 2011). IgM antibodies were also detected infrequently in 
horses that were vaccinated (Jonquiere et al., 2007). Many horses have IgG antibodies due to 
vaccination or as a consequence of an earlier subclinical WNV infection. Moreover, 
antibodies to a broad range of cross-reactive flaviviruses (TBEV, SLEV, etc.) can also be a 
cross-reactive with the antigens in many of the currently available ELISAs. Serological 
diagnosis of WNV infection in North America is confounded by the cross-reactivity of 
antibodies elicited against other flaviviruses, such as SLEV and dengue (Ledermann et al., 
2011) and TBEV in Europe (Ziegler et al., 2012; Rushton et al., 2013). In order to 
demonstrate specific WNV antibodies sera must be run in comparative neutralization tests 
with the relevant viruses. A compilation of the ELISAs for the detection of WNV antibodies 
in horse serum that are available in North America and Europe is given in Table 1.
9. Prophylaxis and treatment
All sensible efforts should be afforded in order to minimize exposure of equids to mosquito 
bites; however, complete shielding of animals housed outdoors from mosquito bites, and 
coincidental WNV exposure, is virtually impossible. As such, minimizing outdoor activities 
during crepuscular time periods and using insecticide repellents has been advised.
The most efficient prevention strategy for WNV infections in horses is certainly vaccinating 
them with licensed vaccines (Table 2). The incursion of WNV into North America provided 
a potent stimulus for development of equine vaccines. The first vaccine licensed in the U.S. 
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was a conventionally inactivated and adjuvanted virus preparation (WEST NILE-
INNOVATOR®, Pfizer). Subsequently, two recombinant vaccines became available, one 
based on a canarypox vector (RECOMBITEK® – Equine rWNV vaccine, Merial) and the 
other a live-attenuated WNV-yellow fever virus chimera (PreveNile™, Intervet). An 
inactivated formulation of the live-attenuated yellow fever chimeric virus (Equi-Nile™; 
Merck) has become subsequently available in the U.S. following the recall of the former. An 
additional inactivated WNV vaccine, Vetera® WNV vaccine (Boehringer Ingelheim), based 
on a 2005 WNV isolate, has been licensed in the U.S. In the E.U. an inactivated vaccine 
(Eqip® WNV (previously Duvaxyn® WNV), Pfizer) was licensed in 2009 and the canarypox 
vector vaccine (Proteq™ WestNile, Merial) in 2011. Each of these vaccines is based on the 
New York 99 isolate of WNV, with the exception of Vetera®, but all are predicted to protect 
against temporal and geographic WNVs in North America as well as alternative WNV 
lineages. In fact, the canarypox vectored vaccine has demonstrated protection in horses from 
a lineage 2 WNV challenge (Minke et al., 2011). Each of these vaccines has been widely 
deployed in the U.S.
There is currently no possibility for a therapeutic intervention in the case of a WNV 
infection other than a symptomatic treatment. These measures include electrolyte infusions 
against dehydration, anti-inflammatory treatment and any means of minimizing/avoiding 
excitation of the animals (e.g. ear plugs to reduce acoustic stimuli, light reduction, etc.) as 
well as extensive padding of the stall and extremities (http://www.youtube.com/watch?
v=BJtVP5Bd5bs). Attempts can be made with parenterally administered conditionally 
licensed (in the U.S.) WNV antibodies, although efficacy studies are lacking (Kutzler et al., 
2008). Furthermore ribavirin and interferon treatment can be attempted, but no efficacy 
studies in horses have been conducted (Robinson and Sprayberry, 2009).
10. Regulations and control measures
According to the OIE Terrestrial Animal Health Code (Chapter 8.16. West Nile fever) the 
following criteria define the occurrence of WN fever (WNF) in equids:
• WNV has been isolated from an animal that shows signs consistent with WNF; or
• viral antigen or viral ribonucleic acid (RNA) specific to WNV has been identified 
in samples from one or more animals that show clinical signs consistent with WNF, 
or that is epidemiologically linked to a confirmed or suspected outbreak of WNF; 
or
• antibodies to WNV have been identified in an unvaccinated animal that shows 
clinical signs consistent with WNF, or that is epidemiologically linked to a 
confirmed or suspected outbreak of WNF.
The foundation for prevention of WNV infection in horses is vaccination, and, as described 
above, several efficacious vaccines are readily available. Control efforts center around 
mosquito abatement and repellents, although implementation of these strategies is difficult 
to achieve in many situations. Due to the low level viremia attained and apparent lack of 
viral shedding, an infected horse appears to pose no direct risk to other animals, including 
humans, except for the obvious concerns in performing a necropsy and being exposed to 
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infective nervous tissue by a veterinarian. Therefore, apart from isolating the affected animal 
mainly for animal welfare reasons, no particular control measures apply. For the same 
reasons there are no trade restrictions for the importation of equines coming from WNF 
infected countries or zones although WNV infection in horses is a reportable disease at the 
federal level and in most states, although quarantines are not generally applied.
11. Open questions
There are still many open questions concerning the WNV infection of equines. More 
research is required to address particularly the following issues:
• What are further molecular modulators triggering the outcome of the infection in 
horses (subclinical versus clinical/fatal)?
• What factors (ecological, veterinary and virological) could potentiate differences in 
the disease progression observed in Europe versus North America?
• Do differences in equine virulence exist between lineage 1 and lineage 2 West Nile 
viral strains?
12. Conclusions
Prior to the 1990s, WNV had been associated with low magnitude equine epizootics in 
Africa, the Middle East and Europe; however, since the mid-90s, WNV has been associated 
with larger scale equine epizootics in new geographic areas for which specific virological, 
ecological, climactic and/or demographic etiologies have not been associated. Newly 
recognized genotypes of WNV have been increasingly associated with pathogenic potential 
such as lineage 2 and lineage 1b (Kunjin) viruses. Equids become infected through the bite 
of enzootic or bridge vectors resulting predominantly in subclinical infection; however, the 
mortality rate of equines that present with clinical disease is high. Due to short and low 
magnitude viremia equids are considered “dead-end” hosts and pose no immanent health 
risk to other animals or humans. The most effective strategy for prevention of equine disease 
is proper vaccination. A number of efficacious equine vaccines have been licensed in the 
U.S. and E.U. including inactivated WN viral vaccines, a canarypox virus vectored 
recombinant and live/killed recombinant yellow fever (17D) chimeric vaccines.
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Structure of West Nile. (a) The WNV virion is composed of an icosahedral core formed by 
positively charged capsid (C) proteins of 12 kDa molecular mass (red). This core is 
enveloped by a host-cell derived membrane in which the major envelope protein E (53 kDa, 
blue dimers) and the membrane protein M (8 kDa, blue capsules) are integrated. C-proteins 
itself enclose an RNA genome encoding for a single open reading frame (ORF) of 10.302 
nucleotides and non-coding regions of 96 and 631 nucleotides at the 5′ and 3′ ends, 
respectively. (b) The WNV genome encodes a polyprotein that is post-translationally 
processed by viral and cellular proteases into five non-structural proteins (NS1, NS2A/
NS2B, NS3, NS4A/NS4B and NS5) and into three structural proteins (C, prM/M and E). E 
protein and prM/M protein (18–20 kDa) virus. (For interpretation of the references to color 
in Figs. 1 and 2 legends, the reader is referred to the web version of this article.)
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This figure is reused from the Journal of Virology, 2011, volume 85 (6), pp. 2964–2974, 
DOI 10.1128/jvi.01963-10 (May et al., 2011), reproduced/amended with permission from 
American Society for Microbiology and kindly provided by Alan Maximum clade 
credibility (MCC) tree of WNV genomes constructed using BEAST version 1.5.3 software. 
Colors of branches indicate geographic locations per the color key. Branch lengths 
correspond to lengths of time, as measured by the scale bar, and the 95% HPD range of 
divergence dates is shown as a bar. The letters at the nodes correspond to data in Table 1. 
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(A) All isolates (with the branch of isolates from the Americas collapsed). (B) Cluster 4 
isolates only (May et al., 2011). Barrett.
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Bird/mosquito transmission cycle of WNV is transmitted in an enzootic passeriform bird–
mosquito (Culex spp. mosquitoes) cycle (green shading). Bridge vectors (such as Aedes 
spp.) can transmit the virus to humans and equines (gray shading) that are designated as 
“dead-end” hosts in that they can become infected but are not capable of serving as a source 
of infection for additional mosquito vectors. Some peridomestic avian hosts (red shading 
and dashed ovals; such as corvids) are capable of developing high titers following infection 
with certain WNV strains and facilitate epidemic amplification. WNV.
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Equine WNF cases reported worldwide officially reported to WAHID/OIE or PROMED or 
published in literature since 1959. Lineage color codes were assigned if at least one horse 
isolate of this lineage was found or if this lineage was the only published lineage occurring 
in this country (for example in humans, birds, mosquitoes).
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Virus Infection and immune response in horses. WNV infected viremia is observed in the 
first six days post-infection and can last 1–6 days (Bunning et al., 2002; Minke et al., 2004; 
Seino et al., 2007). Antibodies can be detected from day 7 or 8 post-infection. Detection of 
IgM is possible for less than 3 months (as reviewed in Castillo-Olivares and Wood, 2004), 
whereas neutralizing antibodies persist for at least 15 months (Ostlund et al., 2001). Clinical 
symptoms are thought to occur mostly after the end of viremia (Castillo-Olivares and Wood, 
2004), nevertheless the onset of symptoms in naturally acquired infections can only be 
estimated. Following mild infections, equines usually recover after two to seven days, but 
may need more than 20 days up to several months for complete reconstitution to their 
original condition (Trock et al., 2001; Venter et al., 2009). In some cases residual signs of 
the infection may even persist (Salazar et al., 2004).
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Serum viremia profiles for 47 horses experimentally infected with WNV NY99 by feeding 
of infected mosquitoes. No horse had a demonstrable viremia beyond 6.5 days post-feeding.
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Table 1
Commercially available ELISAs for the detection of WNV antibodies in horse serum.
Brand name(s) Principle Detected antibodies Antigen WNV lineage Comments





ID Screen® West Nile IgM Capture ELISA Indirect capture ELISA IgM E protein
Lineage 1
IDEXX IgM WNV Ab Test Indirect capture ELISA IgM
Prionics/Ingenasa INGEZIM WEST NILE 
Compac
Competitive ELISA IgG, IgM E protein
Lineage 1
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